MA53660A - Analogues de stérol et leurs utilisations - Google Patents
Analogues de stérol et leurs utilisationsInfo
- Publication number
- MA53660A MA53660A MA053660A MA53660A MA53660A MA 53660 A MA53660 A MA 53660A MA 053660 A MA053660 A MA 053660A MA 53660 A MA53660 A MA 53660A MA 53660 A MA53660 A MA 53660A
- Authority
- MA
- Morocco
- Prior art keywords
- sterol
- analogs
- sterol analogs
- Prior art date
Links
- 229930182558 Sterol Natural products 0.000 title 1
- 150000003432 sterols Chemical class 0.000 title 1
- 235000003702 sterols Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733540P | 2018-09-19 | 2018-09-19 | |
| US201962798752P | 2019-01-30 | 2019-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53660A true MA53660A (fr) | 2021-07-28 |
Family
ID=69888803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053660A MA53660A (fr) | 2018-09-19 | 2019-09-19 | Analogues de stérol et leurs utilisations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220402965A1 (fr) |
| EP (1) | EP3852764A4 (fr) |
| JP (1) | JP2022501348A (fr) |
| CA (1) | CA3112941A1 (fr) |
| MA (1) | MA53660A (fr) |
| WO (1) | WO2020061332A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021010996A2 (pt) | 2018-12-05 | 2021-08-31 | Sage Therapeutics, Inc. | Esteroides neuroativos e seus métodos de uso |
| EP4229208A4 (fr) | 2020-10-14 | 2024-10-30 | George Mason Research Foundation, Inc. | Méthodes de fabrication de nanoparticules lipidiques et compositions dérivées de celles-ci |
| US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
| EP4395748A1 (fr) | 2021-09-03 | 2024-07-10 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
| CN113861258A (zh) * | 2021-09-05 | 2021-12-31 | 中国海洋大学 | 一种马尾藻甾醇的合成方法 |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US20250154193A1 (en) * | 2022-01-28 | 2025-05-15 | Cholesgen (Shanghai) Co., Ltd. | Steroid compound, and preparation method therefor and application thereof |
| EP4469091A1 (fr) | 2022-01-28 | 2024-12-04 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| EP4495130A4 (fr) * | 2022-03-15 | 2025-12-17 | Fujifilm Corp | Composé et composition lipidique |
| WO2023205801A2 (fr) * | 2022-04-22 | 2023-10-26 | Asteroid Therapeutics | Compositions stéroïdiennes et méthodes de traitement de cancers lipogéniques |
| KR20250031230A (ko) | 2022-05-25 | 2025-03-06 | 아카제라 메디신즈, 인크. | 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024089229A1 (fr) | 2022-10-28 | 2024-05-02 | CureVac SE | Formulations améliorées comprenant des transporteurs à base de lipides encapsulant de l'arn |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
| WO2024260570A1 (fr) | 2023-06-23 | 2024-12-26 | CureVac SE | Anticorps codés par un acide nucléique |
| WO2025103803A1 (fr) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunothérapie contre les tumeurs neuronales et cérébrales |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5619000A (en) * | 1979-07-26 | 1981-02-23 | Teijin Ltd | 3beta. 25-dihydroxy-24-oxocholesta-5,7-diene derivative and its preparation |
| US6645953B2 (en) * | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| EP2430168B1 (fr) * | 2009-05-16 | 2016-12-21 | Kunyuan Cui | Compositions comprenant des amphiphiles et des colipides cationiques pour administrer des molécules thérapeutiques |
| EP2457923B1 (fr) * | 2009-07-24 | 2016-01-27 | Kyowa Hakko Kirin Co., Ltd. | Dérivé de stérol |
| ME03091B (fr) * | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines |
| US20150158903A1 (en) * | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20150175651A1 (en) * | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| FR3024361B1 (fr) * | 2014-07-30 | 2017-11-24 | Affichem | Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante |
| ES2793237T3 (es) * | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| CN107312056B (zh) * | 2017-08-24 | 2019-10-25 | 广西师范学院 | 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法 |
| CN107827948A (zh) * | 2017-10-24 | 2018-03-23 | 泰州职业技术学院 | 3β‑乙酰氧基‑17‑芳基雄甾‑5,16‑二烯 |
| JP2022531461A (ja) * | 2019-05-07 | 2022-07-06 | モデルナティエックス インコーポレイテッド | 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法 |
| EP4003296A1 (fr) * | 2019-07-31 | 2022-06-01 | ModernaTX, Inc. | Compositions et méthodes pour le transfert d'agents d'interférence arn à des cellules immunitaires |
| EP4009955A1 (fr) * | 2019-08-07 | 2022-06-15 | ModernaTX, Inc. | Compositions et méthodes pour une administration améliorée d'agents |
-
2019
- 2019-09-19 MA MA053660A patent/MA53660A/fr unknown
- 2019-09-19 CA CA3112941A patent/CA3112941A1/fr active Pending
- 2019-09-19 US US17/277,829 patent/US20220402965A1/en active Pending
- 2019-09-19 WO PCT/US2019/051959 patent/WO2020061332A1/fr not_active Ceased
- 2019-09-19 JP JP2021515073A patent/JP2022501348A/ja not_active Ceased
- 2019-09-19 EP EP19861727.6A patent/EP3852764A4/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3852764A4 (fr) | 2022-06-15 |
| EP3852764A1 (fr) | 2021-07-28 |
| WO2020061332A1 (fr) | 2020-03-26 |
| US20220402965A1 (en) | 2022-12-22 |
| JP2022501348A (ja) | 2022-01-06 |
| CA3112941A1 (fr) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3852764A4 (fr) | Analogues de stérol et leurs utilisations | |
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3291676A4 (fr) | Analogues de la mitragynine et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3870579A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| EP3787607C0 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3661563A4 (fr) | Nanomatériaux biomimétiques et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3866789A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3886843A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3380100A4 (fr) | Inhibiteurs de bromodomaines bivalents et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3484865A4 (fr) | Modulateurs de la somatostatine et leurs utilisations | |
| EP3813946A4 (fr) | Analogues de la rapamycine et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA52092A (fr) | Composés et leurs utilisations | |
| EP4093768A4 (fr) | Constructions cal-t et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3720434A4 (fr) | Mélanges non racémiques et leurs utilisations |